SOHO 2022

Leah SherwoodAggressive B-Cell Lymphoma | October 27, 2022
Does the route of administration matter in preventing CNS relapse in agressive B-cell lymphomas?
Read More
Leah SherwoodAcute Myeloid Leukemia | October 21, 2022
Marina Konopleva, MD, PhD, discusses venetoclax resistance in AML during SOHO 2022
Leah SherwoodMantle Cell Lymphoma | October 17, 2022
Jia Ruan, spoke on emerging treatment options for MCL in this interview from SOHO 2022.
Leah SherwoodMyeloproliferative Neoplasms | October 12, 2022
A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients...
Leah SherwoodAcute Myeloid Leukemia | October 12, 2022
Gilteritinib plus induction and consolidation chemotherapy demonstrated acceptable safety outcomes and efficacy in patients ...
Leah SherwoodAcute Myeloid Leukemia | October 10, 2022
Dr. Konopleva spoke to Blood Cancers Today during the 2022 SOHO Annual Meeting.
Leah SherwoodChronic Lymphocytic Leukemia | October 10, 2022
Dr. Coombs discussed these challenges during the 10th Annual Meeting of the Society of Hematologic Oncology.
Leah SherwoodMeeting News | October 6, 2022
Autologous chimeric antigen receptor (CAR) T-cell therapies have shown
Leah SherwoodTransplantation & Cellular Therapy | October 6, 2022
Carlos de Lima, MD, stopped by the Blood Cancers Today booth at the 2022 SOHO Annual Meeting to give his advice...
Kerri FitzgeraldMantle Cell Lymphoma | October 5, 2022
Event-free survival at 24 months may become an important clinical endpoint in mantle cell lymphoma in the future.
Leah SherwoodMantle Cell Lymphoma | October 5, 2022
Tycel Phillips, MD, discusses the role of targeted therapies in frontline mantel cell lymphoma (MCL).
Leah SherwoodMantle Cell Lymphoma | October 5, 2022
Jia Ruan, MD, PhD, discusses emerging treatment options for mantle cell lymphoma at the 2022 SOHO Annual Meeting.
Leah SherwoodMantle Cell Lymphoma | October 5, 2022
The phase III BRUIN MCL-321 is currently enrolling patients to compare the efficacy of pirtobrutinib versus other Bruton’s ...
Leah SherwoodMantle Cell Lymphoma | October 5, 2022
Updated results from a phase I/IIb study demonstrated promising efficacy for the novel agent pirtobrutinib in heavily ...
Leah SherwoodChronic Lymphocytic Leukemia | October 4, 2022
Catherine Coombs, MD, discusses Bruton’s tyrosine kinase inhibitors at the 2022 SOHO Annual Meeting.
Leah SherwoodChronic Lymphocytic Leukemia | October 3, 2022
Alexey V. Danilov, MD, PhD, spoke with Blood Cancers Today about his 2022 SOHO Annual Meeting presentation.
Leah SherwoodT-Cell Lymphoma | October 3, 2022
The use of extracorporeal photopheresis declined in patients with Sézary syndrome as the COVID-19 pandemic began.
Kerri FitzgeraldAcute Myeloid Leukemia | October 3, 2022
The efficacy of enasidenib in patients with AML depends on the mutation type.
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
A conditioning regimen of clofarabine plus total body irradiation prior to allogeneic hematopoietic stem cell transplantation ...
Cecilia BrownTransplantation & Cellular Therapy | October 2, 2022
Researchers investigated its use in patients undergoing mismatched donor HSCT with post-transplant cyclophosphamide...
Advertisement
Editorial Board

Advertisement